Search Results 681-690 of 16033 for pharmacogenetics
A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ...
Infigratinib is used to treat cholangiocarcinoma (bile duct cancer) that has spread or cannot be removed by surgery. It is used in patients who have already ...
D., is a diagnostic medical physicist, with specialty interest in diagnostic and cone-beam x-ray computed tomography (CT). His clinical focus includes:.
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Bevacizumab blocks the ability of tumors to grow new blood vessels and ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
The purpose of this study is to assess the effectiveness and safety of Lubiprostone in pediatric patients, aged ≥ 6 years to < 18 years, diagnosed with ...
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products ...
Your gift holds great power – donate today! ... Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.
Genitourinary cancers · Penile cancer · Testicular cancer · Prostate cancer · Kidney cancer · Bladder cancer · Ureteral cancer ...
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your GivingTuesday gift can go 2X as far.